
“This assay generates tremendous amounts of data…
to understand the nature of a patient’s tumor. With that understanding, we can guide treatment choices to improve patient outcomes and help patients in their fight against cancer.”
David Spetzler, MS, PhD, MBA
President

Tissue Data
Maximizing Tissue and Data Yield
Caris enhances tissue utilization by cutting sections at 4 microns, enabling more analytical material from small specimens compared to standard approaches. Slides undergo H&E staining, digital scanning and expert pathology review to confirm tumor content and guide downstream testing.
A key differentiator is microdissection, where tumor cells are precisely isolated from surrounding normal tissue, improving sequencing sensitivity and increasing the likelihood of identifying actionable alterations.


Profiling
Comprehensive Molecular Profiling
The laboratory integrates high-volume immunohistochemistry with next-generation sequencing to deliver a complete molecular profile. Using proprietary extraction technology, Caris analyzes DNA and RNA simultaneously, followed by WES and WTS and AI-driven interpretation.
This integrated approach enables:
- Generation of large-scale molecular data to support clinical decision-making and research.
- Identification of actionable biomarkers across DNA, RNA and protein.
- Improved detection sensitivity through tumor enrichment and dual analyte analysis.
- Expanded therapeutic options, including eligibility for targeted and immunotherapies.
Sequencing
Clinical Impact
By combining advanced laboratory processes, comprehensive sequencing and AI-driven analytics, the Caris Tissue Lab supports more informed treatment decisions and helps improve outcomes for patients with cancer.

Ready to order molecular testing?
Our team is here to help you every step of the way.
Contact a Professional


